Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
H2NC10H5(SO3H)SO3K · xH2O
CAS Number:
Molecular Weight:
302.30 (anhydrous basis)
NACRES:
NA.32
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
assay
≥98.0% (HPLC)
impurities
≤8.0% water
mp
>300 °C (lit.)
suitability
suitable for fluorescence
SMILES string
[K+].[H]O[H].Nc1ccc2cc(cc(c2c1)S(O)(=O)=O)S([O-])(=O)=O
InChI
1S/C10H9NO6S2.K.H2O/c11-7-2-1-6-3-8(18(12,13)14)5-10(9(6)4-7)19(15,16)17;;/h1-5H,11H2,(H,12,13,14)(H,15,16,17);;1H2/q;+1;/p-1
InChI key
SHURQDDWGCOLFA-UHFFFAOYSA-M
Application
Monopotassium 7-amino-1,3-naphthalenedisulfonate may be used to conjugate the reducing ends of oligosaccharides, such as those derived from glycoproteins, glycolipids, and proteoglycans, for analysis via gel electrophoresis.
signalword
Danger
hcodes
Hazard Classifications
Eye Dam. 1 - Skin Corr. 1B
Storage Class
8A - Combustible corrosive hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
K B Lee et al.
Carbohydrate research, 214(1), 155-168 (1991-07-18)
A new method is described for sequencing linear oligosaccharides on gels using charged, fluorescent conjugates. The reducing ends of various mono-, di-, tri-, and tetra-saccharides were conjugated with monopotassium 7-amino-1,3-naphthalenedisulfonate (a fluorescent and negatively charged compound) by reductive amination using
Mingyan Hei et al.
American journal of perinatology, 32(8), 725-732 (2014-12-24)
This study aimed to compare the outcomes for symmetrical (sSGA) versus asymmetrical (aSGA) small for gestational age (SGA) < 32 weeks preterm infants. A total of 12,179 eligible infants admitted to the Canadian tertiary neonatal intensive care units (NICUs) over a 7-year-period
David R Holmes et al.
Journal of the American College of Cardiology, 65(24), 2614-2623 (2015-06-20)
The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continued evaluation. This study sought to assess composite data regarding left atrial
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 43184-10G | 04061833336557 |
